PreMD Inc. (fka PREMF)

[small cap investor]

Have you seen this one??


Breast Cancer Clinical Data Accepted for Oral Presentation

Last update: 9:14 a.m. EDT Oct. 21, 2008
TORONTO, Oct 21, 2008 /PRNewswire-FirstCall via COMTEX/ -- Predictive medicine company PreMD Inc. (CA:PMD: news, chart, profile) today announced that an abstract entitled, "Quantitative Galactose Oxidase Schiff's reaction in Nipple Aspirate Fluid may distinguish women with or without Breast Cancer" has been accepted for an oral presentation at the 4th Annual Academic Surgical Congress.
"We are extremely pleased and honored that this abstract has been accepted for presentation at this influential symposium," said Brent Norton, President and CEO of PreMD Inc. "This study provides valuable clinical insight as to how women with breast cancer may benefit from testing with Galactose Oxidase Schiff's (GOS) reactivity. This presentation further strengthens our clinical data of our entire cancer franchise, which we are progressively developing."
This study extends our scientific data and evaluates GOS reactivity in healthy control patients compared to those with ductal carcinoma in situ or invasive disease. The lead author on the study is Dr. Anees B. Chagpar from the University of Louisville. The 4th Annual Academic Surgical Congress is to be held February 3-6, 2009 in Fort Myers, FL